Professionally destroying liquidity for three years, mastering the art of erasing one's position traces. The trading records are dismal, but still full of hope, firmly believing that the next bull run will turn things around. On-chain data analyst, but never used for personal investment.
How Investors May Respond To CStone Pharmaceuticals (SEHK:2616) MHRA Approval Of Sugemalimab For Stage III NSCLC ================================================================================================================
KPN's 2025 Annual Report, titled "Value of Connection," highlights strong results amid digitalization, AI, and sustainability efforts. The report emphasizes growth in all segments and ongoing investments in technology.
Analysts remain optimistic about Arista Networks, with 90% maintaining a bullish stance ahead of fiscal Q4 results. Target prices suggest a potential 27.5% upside, bolstered by strong product demand and AI adoption.
Analysts are bullish on Howmet Aerospace (HWM), with over 80% maintaining a positive outlook and a consensus price target of $240. Recent upward revisions reflect strong sector momentum, supported by increased price targets from firms like Susquehanna and Citi.
BofA maintains a ‘Buy’ rating for McKesson, raising its price target to $970 after robust Q3 results exceeded expectations. The company reported strong revenue and EPS growth, driven by solid performance in its pharmaceutical segments.
Equinor ASA announced a cash dividend of NOK 3.5249 per share for Q3 2025, based on the USDNOK exchange rate. The dividend will be paid on February 27, 2026, to shareholders on Oslo Børs and ADR holders on NYSE.